Evidence map›Paper›PMID 26030844›Full record

ArticlePloS one2015

Cry protein crystals: a novel platform for protein delivery.

Manoj S Nair, Marianne M Lee, Astrid Bonnegarde-Bernard, Julie A Wallace, Donald H Dean, Michael C Ostrowski, Richard W Burry, Prosper N Boyaka, Michael K Chan

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Can (We Make)Toxins · 2021
    Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Manoj S NairDepartment of Chemistry and Biochemistry, The Ohio State University, Columbus, OH, United States of America.
Marianne M LeeDepartment of Chemistry and Biochemistry, The Ohio State University, Columbus, OH, United States of America.
Astrid Bonnegarde-BernardDepartment of Veterinary Biosciences, The Ohio State University, Columbus, OH, United States of America.
Julie A WallaceDepartment of Molecular and Cellular Biology, The Ohio State University, Columbus, OH, United States of America; Tumor Microenvironment Program, The Comprehensive Cancer Center, The Ohio State University, Columbus, OH, United States of America.
Donald H DeanDepartment of Chemistry and Biochemistry, The Ohio State University, Columbus, OH, United States of America.
Michael C OstrowskiDepartment of Molecular and Cellular Biology, The Ohio State University, Columbus, OH, United States of America; Tumor Microenvironment Program, The Comprehensive Cancer Center, The Ohio State University, Columbus, OH, United States of America.
Richard W BurryDepartment of Neuroscience, The Ohio State University, Columbus, OH, United States of America.
Prosper N BoyakaDepartment of Veterinary Biosciences, The Ohio State University, Columbus, OH, United States of America.
Michael K ChanDepartment of Chemistry and Biochemistry, The Ohio State University, Columbus, OH, United States of America.
The Ohio State University · US

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3M
Suppression of Mammary Tumorigenesis by Stromal p53P01CA097189 · NCI · OHIO STATE UNIVERSITY · PI FERNANDEZ, SOLEDAD A · 2004 to 2016
$16.1M
MOLECULAR ADJUVANTS FOR NALT-BASED IMMUNITY TO ANTHRAXR01AI043197 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BOYAKA, PROSPER N · 1998 to 2013
$4.6M
Structural studies of Bacillus thuringiensis Cry ToxinsR21AI081291 · NIAID · OHIO STATE UNIVERSITY · PI CHAN, MICHAEL K · 2009 to 2010
$380k
NCI NIH HHS P01 CA097189NCI NIH HHS P30 CA016058NIAID NIH HHS AI043197NIAID NIH HHS AI081291NIAID NIH HHS R01 AI043197NIAID NIH HHS R21 AI081291
6 · The paper itself

Abstract

Protein delivery platforms are important tools in the development of novel protein therapeutics and biotechnologies. We have developed a new class of protein delivery agent based on sub-micrometer-sized Cry3Aa protein crystals that naturally form within the bacterium Bacillus thuringiensis. We demonstrate that fusion of the cry3Aa gene to that of various reporter proteins allows for the facile production of Cry3Aa fusion protein crystals for use in subsequent applications. These Cry3Aa fusion protein crystals are efficiently taken up and retained by macrophages and other cell lines in vitro, and can be delivered to mice in vivo via multiple modes of administration. Oral delivery of Cry3Aa fusion protein crystals to C57BL/6 mice leads to their uptake by MHC class II cells, including macrophages in the Peyer's patches, supporting the notion that the Cry3Aa framework can be used to stabilize cargo protein against degradation for delivery to gastrointestinal lymphoid tissues.

Indexed as

AnimalsAntigen-Presenting CellsBacillus thuringiensis ToxinsBacterial ProteinsCrystallizationEndotoxinsFibroblastsGreen Fluorescent ProteinsHemolysin ProteinsLuciferasesLuminescent MeasurementsMacrophagesMiceMice, Inbred C57BLPeyer's PatchesProtein EngineeringBacillus thuringiensis ToxinsBacterial ProteinsEndotoxinsGreen Fluorescent ProteinsHemolysin Proteinsinsecticidal crystal protein, Bacillus ThuringiensisLuciferasesRecombinant Fusion Proteins

Identifiers

PMID26030844
PMCPMC4451076
OpenAlexW656247450

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.